Calidi Biotherapeutics presents new preclinical data on TROP2-targeting CLD-501 at T-cell engager summit

Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc.

CLDI

0.00
  • Calidi Biotherapeutics presented new preclinical data on June 24, 2026 for CLD-501, a tumor-targeted T-cell engager program aimed at TROP-2.
  • Results were already presented at the T-Cell Engager Therapeutic Summit, outlining an approach designed to activate T-cells within solid tumors.
  • Data supported localized, in-tumor expression intended to limit off-tumor toxicity risk that has constrained TROP-2 T-cell engager development.
  • The update also highlighted RedTail platform progress, with CLD-401 positioned as the lead candidate and an IND filing targeted by end-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240800PRIMZONEFULLFEED9751622) on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.